



Sterilox Technologies Appoints Gregory T. Bosch as President and Chief Executive Officer

Radnor, PA, October 21, 2004 -- Sterilox Technologies Inc. announced today that its board of directors has elected Gregory T. Bosch as President and Chief Executive Officer effective November 1st 2004.

Prior to joining Sterilox, Mr. Bosch, age 41, held a variety of management and leadership positions with Baxter International during his 19-year tenure. Most recently, he was Vice President and General Manager of Baxter's BioSurgery division, where he led it to become one of the largest biomaterials businesses globally. He has extensive background in the healthcare and laboratory science markets, and brings significant experience in strategic alliances, business development, and international business with assignments in both Austria and Switzerland while with Baxter. He received his BA from Duke University and his MBA from DePaul University.

"Our election of Greg to President and CEO, and the recent appointment of Keith Goldan as our new Chief Financial Officer, shows the board's commitment to the further development of Sterilox Technologies as a world class leader in the fields in which we compete," said Chris Wightman, Sterilox's chairman of the board.

David Anderson, Sterilox's President and CEO for the last four and a half years, will be stepping down from the board at the end of October. "I would like to thank David for all his efforts in the development of our company," said Mr. Wightman.

"I am honored to be leading Sterilox and working with the team and the board to build this company," Bosch said. "This is a very exciting time for Sterilox as we begin to accelerate the utilization of our solutions across their many applications, ultimately benefiting patients and consumers globally."

About Sterilox:

Sterilox Technologies Inc., formed in 1997 and headquartered in Radnor, PA, is a medical technologies company engaged in the development and commercialization of novel solutions based on its patented platform technology. Sterilox has a portfolio of non-toxic, non-hazardous, fast-acting, broad-spectrum biocides. These disinfectants were developed for both rapid and cold sterilization of heat-sensitive surgical instruments such as endoscopes, as well as for general disinfectant use in hospitals and the dental market.

The solutions are produced by Sterilox's patented, electrolytic generators that offer a safe, single-use application for each patient as well as for each disinfecting cycle. They produce a powerful, application specific disinfectant from water and common salt (sodium chloride), eliminating the concern about shelf stability or chemical storage. The Sterilox solutions have multiple use-specific clearances as a high-level disinfectant/sanitizer from the U.S. Food and Drug Administration (FDA) and the U.S. Environmental Protection Agency (EPA), as well as for disinfection and sterilization and as a wound irrigant in the U.K. and Europe. These clearances are supported by one of the largest libraries of disinfectant microbiology

available in the world today.

Eric London (Press Contact)

TSD, Inc.

202-986-0033 x 105

elondon@tsd.biz

Gregory T. Bosch (Corporate Inquiries)

President and CEO

SteriloxTechnologies, Inc.

1-866-369-3130

For more information, visit www.sterilox.com